ATHA Athira Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ATHA

Price (delayed)

$1.92

Market cap

$73.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.09

Enterprise value

-$16.04M

Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira aims to provide rapid cognitive ...

Highlights
The company's debt fell by 17% YoY and by 5% QoQ
ATHA's net income is down by 23% year-on-year but it is up by 2.4% since the previous quarter
The EPS is down by 22% YoY but it is up by 2.5% QoQ
ATHA's quick ratio is down by 46% YoY and by 15% from the previous quarter
ATHA's equity is down by 45% YoY and by 16% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.athira.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ATHA
Market
Shares outstanding
38.33M
Market cap
$73.59M
Enterprise value
-$16.04M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.56
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$117.67M
EBITDA
-$116.49M
Free cash flow
-$101.06M
Per share
EPS
-$3.09
Free cash flow per share
-$2.66
Book value per share
$3.42
Revenue per share
$0
TBVPS
$4.21
Balance sheet
Total assets
$160.25M
Total liabilities
$30.06M
Debt
$1.59M
Equity
$130.19M
Working capital
$125.89M
Liquidity
Debt to equity
0.01
Current ratio
5.37
Quick ratio
5.13
Net debt/EBITDA
0.77
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-59.9%
Return on equity
-69.1%
Return on invested capital
-173.6%
Return on capital employed
-89.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATHA stock price

How has the Athira Pharma stock price performed over time
Intraday
0%
1 week
-9.86%
1 month
-25.87%
1 year
-30.18%
YTD
-20.99%
QTD
-29.93%

Financial performance

How have Athira Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$125.47M
Net income
-$117.67M
Gross margin
N/A
Net margin
N/A
ATHA's net income is down by 23% year-on-year but it is up by 2.4% since the previous quarter
ATHA's operating income is down by 21% YoY but it is up by 3% from the previous quarter

Growth

What is Athira Pharma's growth rate over time

Valuation

What is Athira Pharma stock price valuation
P/E
N/A
P/B
0.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 22% YoY but it is up by 2.5% QoQ
ATHA's equity is down by 45% YoY and by 16% from the previous quarter
ATHA's P/B is 7% below its last 4 quarters average of 0.6

Efficiency

How efficient is Athira Pharma business performance
ATHA's return on equity has dropped by 95% year-on-year and by 13% since the previous quarter
Athira Pharma's ROA has plunged by 78% YoY and by 10% from the previous quarter
The ROIC has contracted by 34% from the previous quarter

Dividends

What is ATHA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATHA.

Financial health

How did Athira Pharma financials performed over time
ATHA's quick ratio is down by 46% YoY and by 15% from the previous quarter
Athira Pharma's current ratio has decreased by 45% YoY and by 14% from the previous quarter
The company's debt is 99% lower than its equity
ATHA's equity is down by 45% YoY and by 16% from the previous quarter
The company's debt fell by 17% YoY and by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.